Company news
Xencor, Inc. (NASDAQ:XNCR) news
Xencor, Inc. news releases on 6ix. Latest, Sep 2, 2026: Xencor to Present at the 2026 Cantor Global Healthcare Conference
Press releases & updates
Xencor to Present at the 2026 Cantor Global Healthcare Conference
September 2, 2026
Xencor Reports Second Quarter 2026 Financial Results
August 5, 2026
Xencor to Receive $105 Million from Alexion to Resolve Ultomiris U.S. Royalty Matter
July 30, 2026
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
July 29, 2026
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
July 17, 2026
Xencor Reports First Quarter 2026 Financial Results
May 5, 2026
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
May 4, 2026
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
March 3, 2026
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
February 24, 2026
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
January 8, 2026
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
December 8, 2025
Xencor to Participate at Upcoming Investor Conferences
November 9, 2025
Xencor Reports Third Quarter 2025 Financial Results
November 4, 2025
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
October 23, 2025
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
October 20, 2025
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 13, 2025
Xencor Reports Second Quarter 2025 Financial Results
August 6, 2025
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
July 30, 2025
Xencor Reports First Quarter 2025 Financial Results
May 6, 2025
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
April 28, 2025
Xencor Appoints Todd Simpson to Board of Directors
March 12, 2025
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
February 26, 2025
Xencor Reports Third Quarter 2024 Financial Results
November 5, 2024
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
November 3, 2024
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
October 9, 2024
Xencor Announces Upcoming Change to Board of Directors
October 3, 2024
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 11, 2024
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
September 10, 2024
Xencor Announces Proposed Public Offering of Common Stock
September 9, 2024
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
September 8, 2024
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
September 5, 2024
Xencor Reports Second Quarter 2024 Financial Results
August 4, 2024
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
June 12, 2024
Xencor Reports First Quarter 2024 Financial Results
May 8, 2024
Xencor Appoints Bart Cornelissen as Chief Financial Officer
April 8, 2024
Xencor to Present at Upcoming Investor Conferences
February 27, 2024
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
February 26, 2024
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
February 19, 2024
Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy
January 1, 2024
Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference
November 20, 2023
Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million
November 6, 2023
Xencor Reports Third Quarter 2023 Financial Results
November 6, 2023
Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting
November 2, 2023
Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023
October 30, 2023
Xencor Announces Planned Retirement of Chief Financial Officer John Kuch
October 25, 2023
Xencor to Present Multiple Posters at the SITC Annual Meeting
September 26, 2023
Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors
September 18, 2023
Xencor Reports Second Quarter 2023 Financial Results
August 2, 2023
Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023
July 26, 2023